Lenvatinib continuation versus regorafenib in treating hepatocellular carcinoma after lenvatinib failure.

Quant Imaging Med Surg · 2026 · PMC12780716 · PMID 41522052

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although there was no significant difference in TPFS or post-second-line PFS between the two groups, the LEN-CON group demonstrated a favorable trend in OS and significantly improved patient survival in subsequent survival analysis.

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.